The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
October 29, 2019
The Annual Report & Long-Range Plan for the 2018-2019 Fiscal Year is now available to view online. Continue reading
October 22, 2019
The purpose of this journal is to keep the nursing community in Florida abreast of important regulatory updates, licensing/renewal information… Continue reading